NASDAQ$PAYS

Paysign Inc · Q3 2021 earnings

Q3 2021 earnings · · Investor relations

Briefing

Reported significant improvements in revenue and operating results.

Paysign reported a solid Q3 2021 with improvements in revenue, loss from operations, EBITDA, and adjusted EBITDA both sequentially and year-over-year. Total revenue for the quarter was $7.8 million, a 16.8% increase from the previous quarter. The company is raising its gross profit margin forecast by 250 basis points to 49.0%.

  • Total revenue for the quarter was $7.8 million, up 16.8% from the second quarter of 2021.
  • Adjusted EBITDA experienced an almost threefold increase over the same period.
  • Gross profit margin forecast raised by 250 basis points to 49.0%.
  • Balance sheet improved sequentially as a result of this quarter’s performance.

Headline financials

Total Revenue

$7.77M

Previous: -$153K+5191.9%
EPS (adj)

-$0.01

Previous: -$0.14+92.9%
Capital Expenditures

-$190K

Previous: -$1.1M+82.7%
Free Cash Flow

-$461K

Previous: -$7.25M+93.6%
Net Income

-$271K

Previous: -$6.15M+95.6%
Operating Income

-$277K

Previous: -$8.42M+96.7%
Gross Profit

$3.97M

Previous: -$3.43M+215.6%
Cash & Equivalents

$70.2M

Previous: $55.5M+26.4%
Total Assets

$83.2M

Previous: $71.1M+17.1%
Stock-Based Comp

$604K

Previous: $799K-24.4%

Revenue & EPS history

Paysign · Revenue · Quarterly

$7.77M

Q3 2021-5,191.9%vs Q3 2020
Beat estimate in 6 of 15 quarters(40%)
ActualEstimate

Forward guidance

Paysign anticipates continued business improvement in Q4 2021, with sequential revenue dollar growth similar to Q3. Gross profit margin forecast is raised to 49.0%.

Tailwinds

  • Sequential revenue dollar growth expected to be similar to Q3.
  • Gross profit margin forecast raised by 250 basis points to 49.0%.
  • Operating expenses are expected to remain flat or increase slightly.
  • Plasma volumes remain at or better than current levels.
  • Adjusted EBITDA forecast is now expected to be in the range of $1.3 million to $1.9 million

Headwinds

  • Residual effects of the pandemic continue to impact the business.
  • Sequential increases in operating expenses expected due to seasonal operational expenditures in Q4.
  • COVID-19 related labor shortages at plasma donation centers.
  • Border closures and other effects continue to weigh on the company’s results of operations.
  • Uncertainty around the extent and timing of the potential future spread or mitigation of COVID-19 and variants.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q3 2021

Historical avgQ3 2021

+16.2%

Avg return

Earnings day

+4.1%

Avg return

5 days after

+7.8%

Avg return

30 days after

44%

27 / 61 earnings

Positive

+900.0%

Q3 2011

Best reaction

-29.6%

Q4 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+37.3%-4.3%
Q1 2026-12.6%-12.0%+4.8%
Q3 2025+0.2%-8.8%+0.4%
Q2 2025+13.0%+4.2%+0.6%
Q1 2025+3.0%+22.9%+81.9%
Q4 2024-8.5%-14.5%-8.1%
Q3 2024+10.9%+8.7%-7.9%
Q2 2024-6.7%-14.4%-9.2%
Q1 2024-0.4%+5.4%-7.6%
Q4 2023+20.5%+10.2%+31.9%
Q3 2023+18.1%+21.6%+18.1%
Q2 2023+6.4%+8.6%+16.0%
Q1 2023-1.8%-4.5%-20.7%
Q4 2022+4.2%+7.6%+0.3%
Q3 2022-10.4%+8.9%+16.5%
Q2 2022+7.4%+15.3%+33.5%
Q1 2022-26.2%-20.2%-2.4%
Q4 2021-6.6%-16.6%-21.4%
Q3 2021-9.0%-14.6%-32.8%
Q2 2021-2.4%+5.6%+16.7%
Q1 2021-11.4%-10.8%+0.0%
Q4 2020+11.7%+5.1%+0.8%
Q3 2020-26.8%-20.6%-7.7%
Q2 2020-18.9%-30.5%-45.3%
Q1 2020-5.5%-13.0%-0.4%
Q4 2019+27.3%+82.9%+102.7%
Q3 2019+13.2%+17.1%+3.9%
Q2 2019+2.5%+6.3%+2.7%
Q1 2019-11.7%-6.7%+18.2%
Q4 2018-1.7%-7.5%-1.0%
Q3 2018-0.5%-1.6%-6.3%
Q2 2018+10.1%+2.7%-2.7%
Q1 2018-0.9%+18.8%+23.1%
Q4 2017+19.0%+20.6%+44.3%
Q3 2017+7.9%+19.3%+15.8%
Q2 2017+2.8%+9.4%+0.0%
Q1 2017-8.7%-6.5%-6.5%
Q4 2016+4.7%+0.0%+0.0%
Q3 2016+34.9%+73.7%+73.7%
Q2 2016+0.0%-5.0%-20.0%
Q1 2016-23.2%
Q4 2015-29.6%
Q3 2015-12.0%
Q2 2015+6.3%
Q1 2015+4.3%
Q4 2014+71.2%
Q2 2014-16.7%
Q1 2014+0.0%
Q4 2013+23.4%
Q3 2013-17.9%
Q2 2013-16.6%
Q4 2012-4.3%
Q1 2013-4.3%
Q3 2012+18.5%
Q2 2012+0.0%
Q1 2012+0.0%
Q4 2011+0.0%
Q3 2011+900.0%
Q2 2011+0.0%
Q1 2011+0.0%
Q4 2010+5.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro